Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
Commentary|Podcasts|December 21, 2023
Public Health Matters: A Pharmacist's Journey in Global Public Health
Tune in to this episode of Public Health Matters for a captivating exploration of global public health through the lens of a pharmacist and traveler.
Advertisement
Host Dr. Christina Madison welcomes a special guest, Nabila Ismail, PharmD, a social media influencer, digital marketer, and passionate traveler. Together, they delve into Nabila's unique journey as a pharmacist exploring global public health, the challenges and triumphs of safely traveling solo, and the importance of advocating for one's health while abroad. Find out more about Nabila
Key Takeaways
- Nabila Ismail's journey serves as an inspiring example of seamlessly blending a health care profession with a love for global exploration.
- Solo travelers, especially women and people of color, can benefit from practical tips for staying safe and healthy while abroad.
- Nabila's personal experiences highlight the importance of adaptability and self-advocacy, particularly when facing health challenges in foreign countries.
- Writing and blogging serve as powerful tools to educate and inform others about the intersection of travel and health care.
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk-funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, though the findings cannot show causation.
Invasive pneumococcal disease may be the first sign of undiagnosed blood cancers and antibody deficiencies in adults, a new study finds.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
In SCOUT-HCM, mavacamten reduced the Valsalva LVOT gradient by 48 mm Hg versus placebo in adolescents. REMS, echo monitoring, and CYP interactions still apply in the new population.
September’s pain management coverage examined postoperative nonopioid options, lessons from sickle cell pain research, and pharmacists’ experiences with controlled-substance prescribing.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
2
September 2026 in Pain Management: 4 Updates on Treatment and Pharmacy Practice
3
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
4
Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
5